Our study included 63 CML patients after imatinib discontinuation, in whom comprehensive analysis of changes in the immune system was performed by flow cytometry, and changes in the BCR::ABL1 transcript levels were assessed by RQ-PCR and ddPCR. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.